Trial Outcomes & Findings for A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) (NCT NCT01733758)

Results Overview

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last nonmissing value before the start of treatment. Change from Baseline was calculated as the value at Week 24 minus the value at Baseline. Based on analysis of covariance (ANCOVA): Change at Week 24 = treatment (placebo, albiglutide 30 mg, albiglutide 50 mg) + Baseline HbA1c + prior diabetes therapy + age category (\<65 years versus ≥65 years). Participants who discontinued from study treatment before Week 24 had their last post-Baseline HbA1c carried forward for the analysis unless the value is past 14 days after the last dose of study drug. The open-label liraglutide group was a reference group and not included in the primary endpoint analysis model. Descriptive summary statistics are provided as a separate outcome measure.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

494 participants

Primary outcome timeframe

Baseline and Week 24

Results posted on

2016-09-22

Participant Flow

A total of 494 participants (par.) were randomized to one of the four treatment groups - placebo (switched to albiglutide 30 mg at Week 24), albiglutide 30 mg, albiglutide 50 mg, liraglutide (open label), 490 par. took at least one dose of study drug (Safety Population). All 490 par. were included in Intent-to-Treat Population.

Participant milestones

Participant milestones
Measure	Placebo Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 milligrams (mg) as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open Label Liraglutide 0.9 mg Daily Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Overall Study STARTED	77	160	150	103
Overall Study COMPLETED	62	148	135	95
Overall Study NOT COMPLETED	15	12	15	8

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 milligrams (mg) as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open Label Liraglutide 0.9 mg Daily Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Overall Study Adverse Event	5	7	8	1
Overall Study Withdrawal by Subject	1	1	5	3
Overall Study Persistent Hyperglycemia	3	2	0	0
Overall Study Protocol Violation	0	1	2	2
Overall Study Non-compliance	1	0	0	0
Overall Study Intro of New Anti-Diabetic Medication	4	0	0	1
Overall Study Inv Decision, HbA1c not controlled	1	1	0	1

Baseline Characteristics

A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=77 Participants Participants received double blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=160 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open Label Liraglutide 0.9 mg Daily n=103 Participants Participants received open label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.	Total n=490 Participants Total of all reporting groups
Age, Continuous	57.3 Years STANDARD_DEVIATION 11.27 • n=5 Participants	59.6 Years STANDARD_DEVIATION 9.00 • n=7 Participants	57.7 Years STANDARD_DEVIATION 9.51 • n=5 Participants	58.4 Years STANDARD_DEVIATION 9.72 • n=4 Participants	58.4 Years STANDARD_DEVIATION 9.70 • n=21 Participants
Sex: Female, Male Female	25 Participants n=5 Participants	35 Participants n=7 Participants	36 Participants n=5 Participants	22 Participants n=4 Participants	118 Participants n=21 Participants
Sex: Female, Male Male	52 Participants n=5 Participants	125 Participants n=7 Participants	114 Participants n=5 Participants	81 Participants n=4 Participants	372 Participants n=21 Participants
Race/Ethnicity, Customized Asian - Japanese Heritage	77 Participants n=5 Participants	160 Participants n=7 Participants	150 Participants n=5 Participants	103 Participants n=4 Participants	490 Participants n=21 Participants

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Intent-to-Treat Population (Last Observation Carried Forward): all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment of HbA1c.

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last nonmissing value before the start of treatment. Change from Baseline was calculated as the value at Week 24 minus the value at Baseline. Based on analysis of covariance (ANCOVA): Change at Week 24 = treatment (placebo, albiglutide 30 mg, albiglutide 50 mg) + Baseline HbA1c + prior diabetes therapy + age category (\<65 years versus ≥65 years). Participants who discontinued from study treatment before Week 24 had their last post-Baseline HbA1c carried forward for the analysis unless the value is past 14 days after the last dose of study drug. The open-label liraglutide group was a reference group and not included in the primary endpoint analysis model. Descriptive summary statistics are provided as a separate outcome measure.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=159 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24	0.25 Percentage of HbA1c in the blood Standard Error 0.068	-1.10 Percentage of HbA1c in the blood Standard Error 0.047	-1.30 Percentage of HbA1c in the blood Standard Error 0.049	—

PRIMARY outcome

Timeframe: Baseline and Week 24

Population: Intent-to-Treat Population (Last Observation Carried Forward): all randomized participants who received at least 1 dose of study treatment and had a Baseline assessment and at least 1 post-Baseline assessment of HbA1c on or before Week 24 provided it was not past more than 14 days after the last dose of study drug intake.

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last nonmissing value before the start of treatment. Change from Baseline was calculated as the value at Week 24 minus the value at Baseline. Participants who discontinued from study treatment before Week 24 had their last post-Baseline HbA1c value carried forward for the summary, unless the value was past 14 days after the last dose of study drug. The open-label liraglutide group was a reference group; descriptive statistics comparing albiglutide and liraglutide were exploratory endpoints.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=159 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=103 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24 Baseline	8.16 Percentage of HbA1c in the blood Standard Deviation 0.877	8.06 Percentage of HbA1c in the blood Standard Deviation 0.783	8.15 Percentage of HbA1c in the blood Standard Deviation 0.825	8.07 Percentage of HbA1c in the blood Standard Deviation 0.787
Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24 Week 24	8.39 Percentage of HbA1c in the blood Standard Deviation 1.066	6.98 Percentage of HbA1c in the blood Standard Deviation 0.735	6.83 Percentage of HbA1c in the blood Standard Deviation 0.659	6.87 Percentage of HbA1c in the blood Standard Deviation 0.642
Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24 Change from Baseline	0.24 Percentage of HbA1c in the blood Standard Deviation 0.715	-1.08 Percentage of HbA1c in the blood Standard Deviation 0.619	-1.32 Percentage of HbA1c in the blood Standard Deviation 0.702	-1.19 Percentage of HbA1c in the blood Standard Deviation 0.636

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: Intent-to-Treat (Observed Case) Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment. Participants who discontinued from study treatment before Week 52 were not included in the analysis. No missing data were imputed.

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3- month period. The Baseline HbA1c value is defined as the last non-missing value on or before the start of treatment. Change from Baseline was calculated as the value at Week 52 minus the value at Baseline.

Outcome measures

Outcome measures
Measure	Placebo n=62 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=148 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=135 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=95 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Change From Baseline in HbA1c at Week 52	-1.07 Percentage of HbA1c in the blood Standard Deviation 0.695	-1.07 Percentage of HbA1c in the blood Standard Deviation 0.790	-1.34 Percentage of HbA1c in the blood Standard Deviation 0.753	-1.17 Percentage of HbA1c in the blood Standard Deviation 0.776

SECONDARY outcome

Timeframe: Week 24

Population: Intent-to-Treat (Last Observation Carried Forward) Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment.

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. Clinically meaningful levels of response in HbA1c are defined as \<6.5% and \<7.0%. Participants who discontinued the study before Week 24 had their last post-Baseline HbA1c value carried forwrad for the summary unless the value was past 14 days after the last dose of study drug.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=159 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=103 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0%) at Week 24 HbA1c <6.5% at Week 24	1 Percentage of participants	31 Percentage of participants	47 Percentage of participants	29 Percentage of participants
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0%) at Week 24 HbA1c <7.0% at Week 24	4 Percentage of participants	92 Percentage of participants	100 Percentage of participants	66 Percentage of participants

SECONDARY outcome

Timeframe: Week 52

Population: Intent-to-Treat (Observed Case) Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment. Participants who discontinued from study treatment before Week 52 were not included in the analysis. No missing data were imputed.

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. Clinically meaningful levels of response in HbA1c are defined as \<6.5% and \<7.0%.

Outcome measures

Outcome measures
Measure	Placebo n=62 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=148 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=135 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=95 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0%) at Week 52 HbA1c <6.5% at Week 52	14 Percentage of participants	44 Percentage of participants	53 Percentage of participants	27 Percentage of participants
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0%) at Week 52 HbA1c <7.0% at Week 52	33 Percentage of participants	82 Percentage of participants	85 Percentage of participants	57 Percentage of participants

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Intent-to-Treat (Last Observation Carried Forward) Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment.

FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the FPG value at Week 24 minus the FPG value at Baseline. Participants who discontinued from study treatment before Week 24 had their last post-Baseline FPG observation carried forward for the summary unless the value was 14 days past the last dose of study drug.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=159 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=103 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 Baseline	159.3 Milligrams per deciliter (mg/dL) Standard Deviation 37.07	157.1 Milligrams per deciliter (mg/dL) Standard Deviation 33.81	158.7 Milligrams per deciliter (mg/dL) Standard Deviation 32.82	157.2 Milligrams per deciliter (mg/dL) Standard Deviation 31.22
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 Week 24	167.0 Milligrams per deciliter (mg/dL) Standard Deviation 37.51	132.2 Milligrams per deciliter (mg/dL) Standard Deviation 26.09	128.8 Milligrams per deciliter (mg/dL) Standard Deviation 24.03	128.1 Milligrams per deciliter (mg/dL) Standard Deviation 23.68
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 Change from Baseline at Week 24	7.7 Milligrams per deciliter (mg/dL) Standard Deviation 31.77	-24.9 Milligrams per deciliter (mg/dL) Standard Deviation 27.58	-30.0 Milligrams per deciliter (mg/dL) Standard Deviation 27.83	-29.1 Milligrams per deciliter (mg/dL) Standard Deviation 29.00

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: Intent-to-Treat (Observed Case) Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment. Participants who discontinued from study treatment before Week 52 were not included in this analysis. No missing data were imputed.

FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value on or before the start of treatment. Change from Baseline was calculated as the FPG value at Week 52 minus the FPG value at Baseline.

Outcome measures

Outcome measures
Measure	Placebo n=62 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=147 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=135 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=95 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 Baseline	154.5 Milligrams per deciliter (mg/dL) Standard Deviation 35.65	154.7 Milligrams per deciliter (mg/dL) Standard Deviation 29.36	159.8 Milligrams per deciliter (mg/dL) Standard Deviation 33.52	157.4 Milligrams per deciliter (mg/dL) Standard Deviation 30.27
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 Week 52	131.7 Milligrams per deciliter (mg/dL) Standard Deviation 23.13	131.9 Milligrams per deciliter (mg/dL) Standard Deviation 24.14	126.3 Milligrams per deciliter (mg/dL) Standard Deviation 24.47	127.0 Milligrams per deciliter (mg/dL) Standard Deviation 20.78
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 Change from Baseline at Week 52	-22.7 Milligrams per deciliter (mg/dL) Standard Deviation 27.38	-22.8 Milligrams per deciliter (mg/dL) Standard Deviation 26.03	-33.5 Milligrams per deciliter (mg/dL) Standard Deviation 31.10	-30.4 Milligrams per deciliter (mg/dL) Standard Deviation 28.06

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Intent-to-Treat (Last Observation Carried Forward) Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment.

The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 24 minus the value at Baseline. Participants who discontinued from the study treatment before Week 24 had their last non-missing weight carried forward for the summary, unless the value is past 14 days after the last dose of study drug.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=159 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=103 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Change From Baseline in Body Weight at Week 24 Baseline	68.65 Kilograms (kg) Standard Deviation 12.088	69.46 Kilograms (kg) Standard Deviation 13.453	71.54 Kilograms (kg) Standard Deviation 12.907	72.65 Kilograms (kg) Standard Deviation 13.758
Change From Baseline in Body Weight at Week 24 Week 24	68.15 Kilograms (kg) Standard Deviation 12.139	69.78 Kilograms (kg) Standard Deviation 13.793	71.50 Kilograms (kg) Standard Deviation 13.023	72.30 Kilograms (kg) Standard Deviation 13.459
Change From Baseline in Body Weight at Week 24 Change from Baseline at Week 24	-0.50 Kilograms (kg) Standard Deviation 1.700	0.32 Kilograms (kg) Standard Deviation 1.795	-0.04 Kilograms (kg) Standard Deviation 1.976	-0.34 Kilograms (kg) Standard Deviation 2.587

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: Intent-to-Treat (Observed Case) Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment. Participants who discontinued before Week 52 from study treatment were not included in the analysis. No missing data were imputed.

The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 52 minus the value at Baseline.

Outcome measures

Outcome measures
Measure	Placebo n=62 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=148 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=135 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=95 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Change From Baseline in Body Weight at Week 52 Baseline	68.07 Kilograms (kg) Standard Deviation 11.978	70.07 Kilograms (kg) Standard Deviation 13.242	71.27 Kilograms (kg) Standard Deviation 12.801	72.43 Kilograms (kg) Standard Deviation 12.895
Change From Baseline in Body Weight at Week 52 Week 52	68.00 Kilograms (kg) Standard Deviation 12.150	70.15 Kilograms (kg) Standard Deviation 13.536	70.96 Kilograms (kg) Standard Deviation 12.431	71.93 Kilograms (kg) Standard Deviation 12.564
Change From Baseline in Body Weight at Week 52 Change from Baseline at Week 52	-0.07 Kilograms (kg) Standard Deviation 2.179	0.08 Kilograms (kg) Standard Deviation 2.078	-0.31 Kilograms (kg) Standard Deviation 2.382	-0.50 Kilograms (kg) Standard Deviation 2.690

SECONDARY outcome

Timeframe: Baseline through Week 52

Population: Intent-to-Treat Population: all randomized par. who received at least 1 dose of study treatment and had a Baseline HbA1c assessment and at least one post-Baseline HbA1c assessment. Par. who did not conform to the protocol-defined criteria of persistent hyperglycemia with respect to FPG values defined above were not included in this analysis.

Participants who experienced persistent hyperglycemia after uptitration were to be withdrawn from the study. Hyperglycemia is defined as a fasting plasma glucose (FPG) ≥280 mg/dL (≥15.5 mmol/L) from ≥Week 2 to \<Week 4, ≥250 mg/dL (≥13.9 mmol/L) from ≥Week 4 to \<Week 12, or ≥230 mg/dL (≥12.8 mmol/L) from ≥Week 12 to \<Week 52, confirmed a second evaluation within 7 days.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=160 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=103 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Time to Study Withdrawal Due to Hyperglycemia	NA Weeks There were too few events of withdrawals due to hyperglycemia to calculate the median and confidence interval.	NA Weeks There were too few events of withdrawals due to hyperglycemia to calculate the median and confidence interval.	NA Weeks There were too few events of withdrawals due to hyperglycemia to calculate the median and confidence interval.	NA Weeks There were too few events of withdrawals due to hyperglycemia to calculate the median and confidence interval.

SECONDARY outcome

Timeframe: Baseline through Week 52

Population: Intent-to-Treat Population: all randomized participants who received at least 1 dose of study treatment and had a Baseline assessment and at least one post-Baseline assessment (scheduled or unscheduled) of the primary endpoint, HbA1c.

Time to withdrawal was calculated as the number of days between the date of first dose and the date of withdrawal plus 1. Time to withdrawal was summarized by visit.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=160 Participants Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 Participants Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open-Label Liraglutide 0.9 mg Daily n=103 Participants Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Time to Study Withdrawal for Any Reason	NA Weeks There were too few events of withdrawals for any reason to calculate the median and confidence interval.	NA Weeks There were too few events of withdrawals for any reason to calculate the median and confidence interval.	NA Weeks There were too few events of withdrawals for any reason to calculate the median and confidence interval.	NA Weeks There were too few events of withdrawals for any reason to calculate the median and confidence interval.

Adverse Events

Placebo - Before Switch

Serious events: 0 serious events

Other events: 33 other events

Deaths: 0 deaths

Placebo - After Switch

Serious events: 0 serious events

Other events: 24 other events

Deaths: 0 deaths

Albiglutide 30 mg Weekly

Serious events: 5 serious events

Other events: 85 other events

Deaths: 0 deaths

Albiglutide 50 mg Weekly

Serious events: 6 serious events

Other events: 76 other events

Deaths: 0 deaths

Open Label Liraglutide 0.9 mg Daily

Serious events: 0 serious events

Other events: 46 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo - Before Switch n=77 participants at risk (Before Switch to 30 mg albiglutide) Participants received double blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24.	Placebo - After Switch n=65 participants at risk (After Switch to 30 mg algiblutide) After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=160 participants at risk Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 participants at risk Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open Label Liraglutide 0.9 mg Daily n=103 participants at risk Participants received open label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric cancer	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lymphoma	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.62% 1/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma cell myeloma	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal Cancer	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.62% 1/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Congenital, familial and genetic disorders Rathke's cleft cyst	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Eye disorders Macular oedema	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.62% 1/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Hepatobiliary disorders Cholecystitis	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.62% 1/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Infections and infestations Pulmonary tuberculosis	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.62% 1/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Nervous system disorders Cerebellar haemorrhage	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.62% 1/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Renal and urinary disorders Renal failure acute	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.

Other adverse events

Other adverse events
Measure	Placebo - Before Switch n=77 participants at risk (Before Switch to 30 mg albiglutide) Participants received double blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24.	Placebo - After Switch n=65 participants at risk (After Switch to 30 mg algiblutide) After Week 24, participants received albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 30 mg Weekly n=160 participants at risk Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.	Albiglutide 50 mg Weekly n=150 participants at risk Participants received double blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to Week 52.	Open Label Liraglutide 0.9 mg Daily n=103 participants at risk Participants received open label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). The dose of 0.9 mg daily was given to Week 52.
Infections and infestations Nasopharyngitis	23.4% 18/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	15.4% 10/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	28.1% 45/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	22.7% 34/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	24.3% 25/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Gastrointestinal disorders Constipation	3.9% 3/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	4.6% 3/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	8.8% 14/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	11.3% 17/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	6.8% 7/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Gastrointestinal disorders Nausea	5.2% 4/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	4.6% 3/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.2% 2/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	6.7% 10/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	3.9% 4/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Metabolism and nutrition disorders Hypoglycaemia	2.6% 2/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	4.6% 3/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	5.0% 8/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	4.0% 6/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	2.9% 3/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Gastrointestinal disorders Diarrhoea	5.2% 4/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.2% 2/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	5.3% 8/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	4.9% 5/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Musculoskeletal and connective tissue disorders Back pain	1.3% 1/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	3.1% 2/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	5.0% 8/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	2.7% 4/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	2.9% 3/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Infections and infestations Bronchitis	2.6% 2/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	3.1% 2/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	2.5% 4/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	5.3% 8/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.9% 2/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Infections and infestations Pharyngitis	1.3% 1/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	8.1% 13/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.67% 1/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.9% 2/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Respiratory, thoracic and mediastinal disorders Upper respiratory tract inflammation	3.9% 3/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	5.0% 8/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.3% 2/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	2.9% 3/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
Skin and subcutaneous tissue disorders Eczema	5.2% 4/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	3.1% 2/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.2% 2/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	2.7% 4/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.9% 2/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.
General disorders Injection site erythema	0.00% 0/77 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.5% 1/65 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	1.9% 3/160 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	6.0% 9/150 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.	0.00% 0/103 • On-therapy non-serious AEs and serious AEs (SAEs), events with an onset on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52. The nonserious AEs and SAEs are reported for the Safety Population, comprised of all participants who received \>= 1 dose of study treatment. Randomized treatment allocation was by design imbalanced in a ratio of 3:6:6:4 for placebo, albiglutide 30 mg, albiglutide 50 mg, and liraglutide. Non-serious AEs excludes hypoglycemia events.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER